- Satellos Bioscience (MSCL) has appointed Philip Lambert, Ph.D., as Chief Technology Officer of the company, effective September 27, 2022
- Dr. Lambert brings more than two decades of experience in pharmaceutical research and development to Satellos
- Satellos is a biotechnology company which develops life-changing medicines to treat degenerative muscle conditions
- Satellos Bioscience Inc. (MSCL) is up 3.03 per cent, trading at C$0.34 per share at 3:47 pm ET
Satellos Bioscience (MSCL) has appointed Philip Lambert, Ph.D., as Chief Technology Officer of the company, effective September 27, 2022.
Dr. Lambert brings more than two decades of experience in pharmaceutical research and development to Satellos. He is a well-published researcher, a serial entrepreneur, and a leader who has held senior positions in academia, biotechnology, non-profit, large pharmaceutical, and contract research organizations.
He is an experienced drug finder who has provided the necessary preclinical data to support the entrance of more than twenty small and large molecule therapeutics into clinical trials for multiple diseases. He was a member of the management team that conducted the due diligence and sale of Sirtris Pharmaceuticals to GlaxoSmithKline for US$720,000,000. He also cofounded, effectively grew, and sold VivoPath, a contract research organization, to Charles River Laboratories.
Dr. Lambert received his Ph.D. in neuroendocrinology from Imperial College London. He was a faculty member in the Department of Psychiatry at Emory University School of Medicine.
Frank Gleeson, MBA, Co-Founder, and CEO of Satellos, commented on the appointment.
“We are thrilled to welcome Dr. Lambert to our team as CTO, leading our translational research and development activities. His in-depth knowledge of pharmacology, drug development and business building will greatly enhance our progress towards discovering and advancing novel medicines that treat rare muscle diseases with unmet medical needs.”
Satellos is a biotechnology company which develops life-changing medicines to treat degenerative muscle conditions.
Satellos Bioscience Inc. (MSCL) is up 3.03 per cent, trading at C$0.34 per share at 3:47 pm ET.
